Showing results (171-180 of 219) with videos related to

Sort By:
Pageof 22
Molecular Cancer Therapeutics|October 10, 2020
Molecular Characterization of Appendiceal Goblet Cell CarcinoidHiroyuki Arai, Yasmine Baca, Francesca Battaglin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 2, 2016
Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice GuidelineDavendra P S Sohal, Pamela B Mangu, Alok A Khorana, et al.
Molecular Cancer Therapeutics|November 2, 2021
Association of Homologous Recombination-DNA Damage Response Gene Mutations with Immune Biomarkers in Gastroesophageal CancersMichael Cerniglia, Joanne Xiu, Axel Grothey, et al.
Cancer Research Communications|May 16, 2022
Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C-Mutant CancersHusain Yar Khan, Misako Nagasaka, Yiwei Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2021
Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513E Gabriela Chiorean, Katherine A Guthrie, Philip A Philip, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2024
Differential Responses to Immune Checkpoint Inhibitors are Governed by Diverse Mismatch Repair Gene AlterationsMoh'd M Khushman, Michael D Toboni, Joanne Xiu, et al.
JAMA Oncology|December 16, 2016
Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical TrialVincent Chung, Shannon McDonough, Philip A Philip, et al.
Future Oncology (London, England)|March 28, 2025
S2303: phase II/III trial of paclitaxel + ramucirumab ± nivolumab in gastric and esophageal adenocarcinoma (PARAMUNE)Anwaar Saeed, Sarah Colby, Paul Eliezer Oberstein, et al.
NPJ Precision Oncology|September 30, 2024
Large-scale analysis of CDH1 mutations defines a distinctive molecular subset with treatment implications in gastric cancerJingyuan Wang, Joanne Xiu, Francesca Battaglin, et al.
Pancreas|December 6, 2012
Systemic treatment in unresectable metastatic well-differentiated carcinoid tumors: consensus results from a modified delphi processJonathan R Strosberg, George A Fisher, Al B Benson, et al.
Pageof 22